نتایج جستجو برای: nhl cell line model
تعداد نتایج: 3815069 فیلتر نتایج به سال:
Although new targeted therapies, such as ibrutinib and idelalisib, have made a large impact on non-Hodgkin's lymphoma (NHL) patients, the disease is often fatal because patients are initially resistant to these targeted therapies, or because they eventually develop resistance. New drugs and treatments are necessary for these patients. One attractive approach is to inhibit multiple parallel path...
Non-Hodgkin lymphomas (NHLs) are a heterogeneous group of hematologic malignancies which typically respond to standard first-line chemoimmunotherapy regimens. Unfortunately, patients with refractory NHL face a poor prognosis and represent an unmet need for improved therapeutics. We present two cases of refractory CD30+ NHL who responded to novel brentuximab vedotin- (BV-) based regimens. The fi...
BACKGROUND/AIMS In Asia, the incidence of non-Hodgkin lymphoma (NHL) has increased in recent decades. Waldeyer's ring (WR) is the most common site of NHL involving the head and neck. In this study, the pathological distribution of WR-NHL and its clinical features were analyzed retrospectively. METHODS From January 2000 through December 2010, we analyzed the medical records of 328 patients fro...
Lymphomas are solid tumors of immune system and Non-Hodgkin Lymphomas (NHL) is the most prevalent lymphomas; with wide ranges of histological and clinical features, it is so difficult to identify them. Herein, various bioinformatics tools (such as gene differential expressions, epigenetics and protein analysis) employed to find new treatment approach for NHL based on gene expression variation b...
BACKGROUND Radioimmunotherapy (RIT) is a safe and effective therapeutic option for patients with indolent B-cell non-Hodgkin lymphomas (NHL), in both up-front and relapsed/refractory settings. Two approved agents (90Y-ibritumomab tiuxetan and 131I-tositumomab) are available in the United States. Both target CD20 with similar clinical outcomes but with unique clinical considerations and radiatio...
abstract objectives: tumour necrosis factor α (tnfα) and lymphotoxin α (ltα) have been implicated in the pathogenesis of lymphoproliferative disorders. patients with b-cell non-hodgkin’s lymphoma (nhl) often have high serum levels of tnf which may be associated with a poor outcome. tnfα and ltα polymorphisms are known to influence expression of these cytokines and may explain the variable respo...
Recently, bendamustine has become an important agent in the treatment for patients with lymphoid malignancies. Although the drug has received approval for second-line therapy in indolent lymphoma, a growing body of evidence suggests its efficacy and safety in first-line use. The results of randomised and observational studies with bendamustine as front-line therapy in non-Hodgkin lymphoma (NHL)...
ovarian cancer is the most lethal gynecological cancer in which cisplatin-based treatment plays fundamental role as the first line chemotherapy option. however, development of platinum-resistance is a critical and poorly understood problem in ovarian cancer treatment. although in vitro generation of platinum-resistant ovarian cancer cell lines is a long established approach to uncover the molec...
Purpose:Chemokine axis CXCR4/CXCL12 is critically involved in the survival and trafficking of normal andmalignant B lymphocytes.Here,we investigated the effect of high-affinityCXCR4antagonist BKT140on lymphoma cell growth and rituximab-induced cytotoxicity in vitro and in vivo. Experimental Design: In vitro efficacy of BKT140 alone or in combination with rituximab was determined in non-Hodgkin ...
BACKGROUND Rituximab-containing salvage chemotherapy has shown promising efficacy in patients with relapsed/refractory B-cell non-Hodgkin's lymphoma (NHL). The aim of this study was to examine the efficacy of rituximab-containing treatment in patients with B-cell NHL who developed relapsed or refractory disease after prior rituximab use and to explore the predictive factors of response using th...
نمودار تعداد نتایج جستجو در هر سال
با کلیک روی نمودار نتایج را به سال انتشار فیلتر کنید